International Journal of Radiation Oncology * Biology * Physics
Volume 44, Issue 2 , Pages 333-341 , May 1999

Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation

  • Karl Wurstbauer, M.D.

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria
    • Corresponding Author InformationReprint requests to: Dr. Karl Wurstbauer, LKA Salzburg, Institue of Radiotherapy and Radio-Oncology, Mullner Haupstr. 48, A-5020, Salzburg, Austria
    • ,
  • Heinz Deutschmann (M.Sc.)

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria
    • ,
  • Manfred Kranzinger, M.D.

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria
    • ,
  • Florian Merz, Ph.D.

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria
    • ,
  • Hassan Rahim, Ph.D.
    • ,
  • Felix Sedlmayer, M.D.

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria
    • ,
  • H.Dieter Kogelnik, M.D.

      Affiliations

    • Institute of Radiotherapy and Radio-Oncology, LKA Salzburg, Salzburg, Austria

,Accepted 23 November 1998.

References 

  1. American Cancer Society. Cancer facts and figures. Atlanta; 1996.
  2. Travis W, Linder J, Mackay B. Classification, histology, cytology and electronmicroscopy. In: Pass H, Mitchell J, Johnson D; et al., editors. Lung cancer, principles and practice. Philadelphia: Lippincott-Raven; 1996; p.361–395.
  3. Arriagada R, le Chevalier T, Quiox E, et al.  ASTRO plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomised study of 353 patients. Int J Radiat Oncol Biol Phys. 1991;20:1183–1190
  4. Cox JD, Azarnia N, Byhardt RW, et al.  Randomised phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543–1555
  5. Fu X-L, Jiang G-L, Wang L-J, et al.  Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: Clinical phase I/II trial. Int J Radiat Oncol Biol Phys. 1997;39:545–552
  6. Herskovic A, Farnan N, Demas W, et al.  Tolerance and toxicity of T.I.D. accelerated hyperfractionated radiation therapy for bronchogenic cancer - RTOG 92–05. (Abstr.) Int J Radiat Oncol Biol Phys. 1995;32(Suppl. 1):278
  7. Komaki R, Scott CB, Sause WT, et al.  Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer. Faillure patterns by cell type in RTOG 88– 08/ECOG 4588. Int J Radiat Oncol Biol Phys. 1997;39:537–544
  8. Saunders MI, Dische S, Barrett A; et al., on behalf of the CHART Steering Committee. Randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Br J Cancer 1996;73:1455–1462.
  9. Sause WT, Scott C, Taylor S, et al.  Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 45-88: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  10. Blanke R, Ansari R, Mantravadi R, et al.  Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer. A Hoosier Oncology Group protocol. J Clin Oncol. 1995;13:1425–1429
  11. Jeremic B, Jevremovic S, Mijatovic L, et al.  Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer. Cancer. 1993;71:3732–3736
  12. Jeremic B, Shibamatu Y, Acimovic L, et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatine/etoposide for stage III non-small cell lung cancer: A randomised study. J Clin Oncol. 1996;14:1065–1070
  13. Komaki R, Scott C, Ettinger D, et al.  Randomized phase II study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group 92-04. Proc Am Soc Clin Oncol. 1996;15:A1656
  14. Lee JS, Scott C, Komaki R, et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: RTOG protocol 91-06. J Clin Oncol. 1996;14:1055–1064
  15. Schaake-Koning C, Van den Bogaert W, et al.  Effects of concommitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–530
  16. Trovo MG, Minatel E, Franchin G. ; et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24:11–15
  17. Armstrong J, Burman C, Leibel S, et al.  Conformal three dimensional treatment planning may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 1993;26:685–689
  18. Armstrong J, Raben A, Zelefsky M, et al.  Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  19. Armstrong JG. Target volume definition for three dimensional conformal radiation therapy of lung cancer. Br J Radiol. 1998;71:587–594
  20. Graham MV, Drzymala RE, Jain NL, et al.  Confirmation of dose-volume histograms and normal tissue complications after radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1994;30(Suppl. 1):198
  21. Graham MV, Matthews JW, Harms WB, et al.  Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1994;29:1105–1107
  22. Graham M, Purdy J, Emami B, et al.  Preliminary results of a prospective trial u sing three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995;33:993–1000
  23. Hazuka MB, Turrisi AT, Lutz ST, et al.  Results of high-dose thoracic irradiation incorporating beams’s eye view display in non-small cell lung cancer: A retrospective multivariate analysis. Int J Radiat Oncol Biol Phys. 1993;27:273–284
  24. Leibel SA. The biologic basis for conformal three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:805–811
  25. Lichter AS. Three-dimensional conformal radiation therapy: A testable hypothesis. Int J Radiat Oncol Biol Phys. 1991;21:853–855
  26. Lichter AS, Sandler HM, Robertson JM, et al.  Clinical experience with three-dimensional treatment planning. Semin Radiat Oncol. 1992;2:257–266
  27. Robertson JM, Kessler ML, Lawrence TS. Clinical results of three-dimensional conformal irradiation. J Natl Cancer Inst. 1994;86:968–974
  28. Robertson JM, Ten Haaken RK, Mazuka MB, et al.  Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1079–1085
  29. Sibley GS, Mundt AJ, Shapiro C, et al.  The treatment of stage III non-small cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33:1001–1007
  30. Vijayakumar S, Myrianthopoulos LC, Rosenberg I, et al.  Optimization of radical radiotherapy with beam’s eye view techniques for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1991;21:779–788
  31. Emam B, Lyman J, Brown A, et al.  Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  32. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: Lippincott Co.; 1992. p.115–122.
  33. ICRU-50. Prescribing, recording, reporting, photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1994.
  34. CHART Steering Committee Saunders MI. A randomised multicentre trial of CHART vs. conventional radiotherapy in non-small cell lung cancer. Lung Cancer. 1997;18:28–29
  35. King SC, Acker JC, Kussin MD, et al.  High dose, hyperfractionated accelerated radiotherapy utilising a concurrent boost for treatment of non-small cell lung cancer: Unusual toxicity and promising early results. Int J Radiat Oncol Biol Phys. 1996;36:593–599
  36. Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol. 1996;6:92–97
  37. Leibel SA, Armstrong JG, Kutcher GJ; et al. 3-D conformal radiation therapy for non-small cell lung carcinoma. In: Meyer JL, Purdy JA, editors. 3-D conformal radiotherapy. Vol. 29. Basel, Karger; 1996.p. 199–206.

PII: S0360-3016(99)00021-8

International Journal of Radiation Oncology * Biology * Physics
Volume 44, Issue 2 , Pages 333-341 , May 1999

Article Tools

* Image Usage & Resolution